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through IGF-1 signaling
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Jeryl Hauptman,3 Magdy Girgis,3 and Buddhadeb Dawn3,4,*
SUMMARY
Although vitamin D3 (VitD3) prevents angiogenesis in cancer, VitD3 deficiency is
associated with greater incidence of cardiovascular events in patients. We exam-
ined the influence of VitD3 on the angiogenic potential of mesenchymal stem cells
(MSCs). VitD3 treatment increased the expression of proangiogenic molecules in
MSCs, which exhibited an endothelial cell-like phenotype and promoted vascular-
ization in vitro and in vivo. VitD3 activated the IGF-1 promoter and boosted IGF-1
receptor (IGF-1R) signaling, which was essential for the mesenchymal-to-endo-
thelial transition (MEndoT) of MSCs. VitD3-treated MSCs created a proangio-
genic microenvironment for co-cultured arterial endothelial cells, as well as aortic
rings. The induction of MEndoT and angiogenesis promotion by VitD3-stimulated
MSCs was attenuated by IGF-1R inhibitor picropodophyllin. We conclude that
VitD3 promotes MEndoT in MSCs, and VitD3-treated MSCs augment vasculariza-
tion by producing a proangiogenic niche through continued IGF-1 secretion.
These results suggest a potential therapeutic role of VitD3 toward enhancing
MSC-induced angiogenesis.
INTRODUCTION
Bonemarrowmesenchymal stem cells (MSCs) have been shown to promote angiogenesis after an ischemic
injury (Nagaya et al., 2004). Under specific culture conditions, a small fraction of MSCs express endothelial
characteristics (Prockop, 1997). MSCs also participate in angiogenesis through paracrine factors, including
vascular endothelial growth factors (VEGFs) and basic fibroblast growth factor (Kinnaird et al., 2004b). How-
ever, the results of clinical trials for therapeutic tissue repair with MSCs have produced suboptimal results.
Although vitamin D3 (VitD3) deficiency has been linked to manifold adverse health consequences (Holick,
2006), the underlying pathophysiology and molecular mechanisms remain largely unclear. The effects of
VitD3 on angiogenesis remain particularly perplexing. VitD3 has also been shown to suppress endothelial
cell sprouting and proliferation in vitro and reduce vascularity of tumors in vivo (Mantell et al., 2000). How-
ever, a role of VitD3 in the promotion of vascular regeneration through the SDF-1/CXCR4 axis and recruit-
ment of angiogenic myeloid cells has been reported (Wong et al., 2014). The ability of VitD3 to enhance
proliferation and migration of endothelial cells has also been documented (Molinari et al., 2013). In addi-
tion, epidemiological data from VitD3-deficient patients show an increased incidence of cardiovascular
events (Wang et al., 2008), suggesting its possible proangiogenic influence.
Given the therapeutic potential of MSCs in cardiac repair (Golpanian et al., 2016), we sought to determine
whether VitD3 treatment could induce a proangiogenic phenotype in MSCs and promote vascularization.
We further investigated the impact of VitD3 treatment on MSC niche. Although a positive association be-
tween serum 25(OH)D levels and IGF-1 concentration in humans has been reported (Hypponen et al., 2008),
the potential molecular basis remains unknown. Since IGF-1 is known to promote angiogenesis (van Beij-
num et al., 2017) and has been reported to increase levels of VEGF and its receptors in certain cells (Menu
et al., 2004; Rabinovsky and Draghia-Akli, 2004), we examined whether VitD3 treatment would induce
mesenchymal-to-endothelial transition (MEndoT) through IGF-1 upregulation. Our results indicate that
VitD3 induces MEndoT in MSCs and augment angiogenesis in a dose-dependent manner. Perhaps
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more importantly, our findings also show that VitD3-treatedMSCs are able to create a proangiogenic niche
through increased IGF-1 secretion.
RESULTS
VitD3 induces proangiogenic genes and proteins in MSCs
The role of VitD3 in angiogenesis remains poorly understood. To examine the angiogenic potential of
VitD3, we first examined whether exposure to VitD3 would increase the expression of molecules known
to promote angiogenesis. MSCs were harvested from murine bone marrow by adhesion and expanded
in culture. To analyze the expression profile of these genes, total RNA was extracted from MSCs after
48 h of treatment with VitD3 (0.1 nM and 10 nM) or dimethyl sulfoxide (DMSO, control). Quantitative poly-
merase chain reaction (qPCR) data in Figure 1A show that VitD3 treatment upregulated the expression of
proangiogenic genes, including VEGF, FLK1, endothelin-1, VCAM-1, ICAM-1, VWF, and VE-cadherin in a
dose-dependent fashion. The levels of 2 key proangiogenic molecules, VEGF and its receptor FLK1,
increased 12.4- and 3.9-fold, respectively, with 10 nM of VitD3 (Figure 1A). Increased VEGF and FLK1 levels
byWestern blot analysis confirmed the above mRNA findings at the protein level (Figures 1B and 1C). Inter-
estingly, the expression of genes associated with cellular pluripotency such as Oct-4 and SSEA1 was also
upregulated by VitD3 treatment (Figure 1A).
VitD3 induces mesenchymal-to-endothelial transition in MSCs
Since the ability of VitD3 to induce endothelial transition in MSCs remains unknown, we examined whether
VitD3 could induce this phenotypic shift in MSCs. Treatment of MSCs with VitD3 for 48 h increased VE-cad-
herin and CD34 protein levels in a dose-dependent manner (Figures 2A and 2B). These results were further
validated by staining of MSCs with fluorophore-conjugated anti-VE-cadherin and anti-CD34 antibodies. As
shown in Figure 2C, compared with control MSCs, VitD3-treated MSCs exhibited increased fluorescent
Figure 1. VitD3 induces proangiogenic molecules in MSCs
(A) qPCR data show increased mRNA levels of proangiogenic as well as pluripotency-related genes in MSCs following
exposure to VitD3. Data represent mean G standard error of the mean (SEM), n = 3.
(B) RepresentativeWestern immunoblots show VEGF, FLK1, and b-actin (loading control) protein levels in MSCs following
VitD3 stimulation.
(C) Densitometric quantitation of VEGF and FLK1 protein levels.
Data represent mean G SEM. One-way analysis of variance (ANOVA) with Bonferroni post hoc test, ns = not significant,
*p < 0.05, **p < 0.01, ****p < 0.0001, n = 3.
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signals indicating greater expression of VE-cadherin and CD34. As VE-cadherin is essential for cohesion
and organization of the intercellular junctions of endothelial cells, it is a reliable indicator of an endothelial
phenotype (Breier et al., 1996). These observations therefore suggest that a significant fraction of VitD3-
treated MSCs acquire an endothelial-like cellular phenotype.
To quantify the extent of MEndoT, control and VitD3-treated MSCs were stained with fluorescent conju-
gated antibodies against CD34 and CD31, two known markers of endothelial lineage (Middleton et al.,
2005). Flow cytometric analysis identified a dose-dependent increase in CD34+ MSCs by 1.5- and 3.5-folds
in 0.1 nM and 10 nM VitD3-treated MSC groups, respectively, compared with control MSCs (Figure 2D).
Interestingly, CD31 expression did not increase significantly following VitD3 treatment, indicating early
commitment to endothelial lineage.
VitD3-treated MSCs induce angiogenesis in vitro and in vivo
To determine the significance of the above molecular changes, we examined whether MEndoT in VitD3-
treated MSCs would translate into angiogenesis. MSCs were treated with VitD3 for 48 h, and angiogenesis
assays were performed in vitro on Matrigel. Compared with controls, VitD3 treatment resulted in greater
Figure 2. VitD3 induces MEndoT in MSCs
(A) Representative Western immunoblots show VE-cadherin, CD34, and b-actin (loading control) expression in MSCs
following VitD3 stimulation.
(B) Densitometric quantitation of VE-cadherin and CD34 protein levels. Data represent mean G standard error of the
mean (SEM). One-way analysis of variance (ANOVA) with Bonferroni post hoc test, ns = not significant, *p < 0.05, ***p <
0.001, ****p < 0.0001, n = 3.
(C) Increased expression of CD34 (FITC, green) and VE-cadherin (TRITC, red) in MSCs following VitD3 treatment. Nuclei
are identified in blue (DAPI). Scale bar, 20 mm.
(D) Flow cytometric analysis shows a dose-dependent increase in CD34 expression and minimal expression of CD31 in
VitD3-stimulated MSCs. The right part shows the quantitative data. Data represent mean G SEM. One-way ANOVA with
Bonferroni post hoc test, ****p < 0.0001, n = 3.
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tube formation by MSCs (Figure 3A), which quantitatively resulted in 2.68- and 11.76-fold greater branch
lengths in 0.1 nM and 10 nM VitD3-treated MSCs groups (Figure 3B), respectively.
Next, we performed a xenograft assay to examine whether MSCs were capable of promoting angiogenesis
in vivo. Control Matrigel plugs or those mixed with VitD3-treated MSCs were transplanted subcutaneously
in 8-week-old C57BL/6 male mice. Three weeks later, explanted Matrigel plugs carrying VitD3-treated
MSCs macroscopically displayed a pink color indicating perfusion with blood in vivo as compared with a
pale color observed in control MSC plugs (Figure 3C). The 10 nM VitD3-treated group showed a signifi-
cantly darker change in coloration. This indicated the presence of larger amount of blood, which suggested
a higher density of functional capillaries, an early stagemarker of neovascularization produced by endothe-
lial cells (Akhtar et al., 2002). Sections from Matrigel plugs were stained with isolectin B4 (Figure 3D) and
capillary densities quantified using microscopy. The capillary densities were 1.41- and 2.46-folds greater
in the 0.1 nM and 10 nM VitD3-treated MSC groups, respectively (Figure 3E). Together, these data indicate
that MSCs treated with VitD3 are able to induce greater angiogenesis both in vitro and in vivo.
VitD3 induces and activates the IGF-1 proangiogenic signaling pathway
To elucidate the mechanistic basis of the above observations, we investigated the molecular events that
lead to MEndoT of VitD3-treated MSCs. Earlier, we observed that the expression of IGF-1 in MSCs was
significantly enhanced following VitD3 treatment (Figure 1A). To further validate this finding, protein
expression of IGF-1 was assessed by Western blot analysis following 48 h of VitD3 treatment. We found
Figure 3. VitD3-treated MSCs promote angiogenesis in vitro and in vivo
(A) MSCs treated with either vehicle (control) or VitD3 produced a tube-like network in a Matrigel assay. Scale bar, 1 mm.
(B) Quantitative assessment of relative branch length. Data represent meanG standard error of the mean (SEM), Welch’s
analysis of variance (ANOVA) with Dunnett’s T3 post hoc test, *p < 0.05, **p < 0.01, n = 4.
(C) Explanted Matrigel plugs with vehicle- (control) or VitD3-treated MSCs show evidence of perfusion with blood. n = 6
per group.
(D) Isolectin B4 positivity (green) identifies capillary endothelium withinMatrigel plugs at 3 weeks after implantation. Scale
bar, 10 mm.
(E) Quantitative estimates of capillary densities in Matrigel plugs. Data represent mean G SEM. One-way ANOVA with
Bonferroni post hoc test, ns = not significant, **p < 0.01, n = 4 per group.
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Figure 4. VitD3 enhances proangiogenic IGF-1 signaling in MSCs
(A and B) Representative Western immunoblots (A) and quantitative densitometric data (B) show increased protein
expression of key components of IGF-1 signaling in VitD3-treated MSCs in a dose-dependent manner. Data represent
mean G standard error of the mean (SEM). Welch’s analysis of variance (ANOVA) with Dunnett’s T3 post hoc test (IGF-1
and p-IGF-1R) and one-way ANOVA with Bonferroni post hoc test (p-ERK1/2), ns = not significant, *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001, n = 3.
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significant upregulation of IGF-1 by VitD3 in a dose-dependent manner (Figures 4A and 4B). In light of
these results, we examined the activation of IGF-1 receptor (IGF-1R) via phosphorylation. The phospho-
IGF-1R levels increased by 1.28-, 1.60-, and 1.79-folds in 0.1 nM, 1 nM, and 10 nM VitD3-treated MSC
groups, respectively. In addition, we found concomitant increases in the activation of a key downstream
factor for angiogenesis, phospho-ERK1/2 (Dunn et al., 2001) (Figures 4A and 4B). To further interrogate
the role of IGF-1 signaling in VitD3-treated MSCs, we analyzed IGF-1R signaling using a specific inhibitor,
picropodophyllin (PPP). The VitD3-induced increase in phospho-IGF-1R, phospho-ERK1/2, VEGF, and
FLK1 was reduced by co-treatment with PPP, and this suppression was also dose dependent (Figures 4C
and 4D).
Although IGF-1 signaling has been shown to promote angiogenesis, its role in MSC-induced angiogenesis
remains unknown. To address this, qPCR was performed to examine the relative levels of mRNA transcripts
encoding proangiogenic factors following treatment with VitD3 with or without PPP. VitD3 treatment re-
sulted in marked increase in mRNA expression of several proangiogenic and pluripotency-related mole-
cules. PPP co-treatment reversed these changes with suppression of VitD3-induced augmentation of
mRNA expression of endothelin-1, VCAM-1, ICAM-1, VE-cadherin, VWF, PDGFRb, a-SMA, CD34, FLK1,
and VEGF (Figure 4E), indicating that VitD3-induced activation of IGF-1R signaling is responsible for the
induction of a proangiogenic phenotype in MSCs.
To further substantiate these findings at themRNA level, we performedWestern blot analysis using protein
samples from cells subjected to analogous treatments. The results confirmed similar effects of PPP co-
treatment on protein levels of VE-cadherin and CD34 (Figure 5A). Finally, MSCs treated with VitD3 with/
out PPP for 48 h were stained with anti-VE-cadherin and anti-CD34 antibodies followed by fluorescent im-
aging. Consistently, the VitD3-induced increase in fluoresence signals of VE-cadherin and CD34 was mark-
edly reduced in MSCs co-treated with PPP (Figure 5B).
VEGF and FLK1 (Figures 4C and 4D) are two of the most important proangiogenic signaling molecules.
Thus, suppression of VEGF and FLK1 expression by PPP indicated a negative impact of PPP on angiogen-
esis by MSCs. To examine this, VitD3-treated MSCs with or without PPP co-treatment were subjected to an
in vitro angiogenesis assay on Matrigel. As shown in Figure 5C, the branch formation competence of MSCs
was greatly reduced by PPP. Compared with untreated MSCs (control), branch length increased by 11.76-
fold in the VitD3-treated MSC group, which was reduced to a mere 3.45-fold increase with PPP co-treat-
ment (Figure 5D). The suppression of both angiogenesis-related gene expression and branch formation
by IGF-1R inhibitor PPP indicates that IGF-1, through the expression of VEGF-FLK1, is a major factor
contributing to the angiogenesis-promoting effects of VitD3 in MSCs.
IGF-1 identified as the target gene for VitD3
The functions of VitD3 are predominantly activated through binding to its specific receptor, the vitamin D
receptor (VDR) (Brumbaugh and Haussler, 1973). To determine whether the VitD3-VDR complex is a tran-
scriptional activator of IGF-1, chromatin immunoprecipitation (ChIP) assay was performed for IGF-1 in
response to VitD3 treatment of MSCs. The results of the ChIP assay indicated that VDR directly binds to
the promoter region of IGF-1 and that this binding was more robust in the presence of increasing doses
of VitD3 (Figure 6A). Compared with untreated MSC controls, the VDR binding activities were 7.28- and
43.76-folds greater in MSCs treated with 0.1 nM and 10 nM of VitD3, respectively (Figure 6B).
Furthermore, the analysis of murine IGF-1 genomic sequence identified two potential VDR response ele-
ments in the promoter region of IGF-1. Next, to evaluate whether these response elements within the
IGF-1 promoter confer VitD3 and VDR-dependent transcriptional activation, luciferase assay was per-
formed. A DNA fragment of the IGF-1 promoter was subcloned into the firefly luciferase reporter vector,
Figure 4. Continued
(C and D) Representative Western immunoblots (C) and quantitative densitometric data (D) show reversal of VitD3-
induced expression of proangiogenic molecules following co-treatment with PPP, an IGF-1R antagonist, in a dose-
dependent manner. Data represent mean G SEM. Welch’s ANOVA with Dunnett’s T3 post hoc test (p-IGF-1R and p-
ERK1/2) and one-way ANOVA with Bonferroni post hoc test (VEGF and FLK1), ns = not significant, *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001, n = 3.
(E) qPCR data show reversal of VitD3-induced increased expression of proangiogenic genes following co-treatment with
PPP, an IGF-1R antagonist. Data represent mean G SEM, n = 3.
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pGL3-Basic (renamed IGF-1-WT). In addition, the VDR binding elements within the IGF-1 promoter region
were mutated and subcloned into the pGL3-Basic vector and renamed IGF-1-mut1 and IGF-1-mut2 (Fig-
ure 6C). As shown in Figure 6D, the induction of the luciferase signal was enhanced by 1.43- and 4.32-folds
in MSCs treated with 0.1 nM and 10 nM of VitD3, respectively, compared with controls, suggesting that
VitD3, through its activation of the VDR, can activate IGF-1 expression. The respective reporter signals
of the IGF-1-mutants induced by VitD3 were considerably less when compared with the wild-type IGF-1
promoter vector (IGF-1-WT) during stimulation with the same concentrations of VitD3 (Figure 6D), confirm-
ing the role of VDR binding to IGF-1 promoter in response to VitD3 stimulation.
VitD3-treated MSCs promote a proangiogenic niche
MSCs have the ability to generate a specificmicroenvironment through the secretion of various factors (Kin-
naird et al., 2004a, 2004b). Our results show the ability of VitD3 treatment to induce IGF-1 expression in
Figure 5. IGF-1R antagonist inhibits both MEndoT and the proangiogenic phenotype of VitD3-treated MSCs
(A) Representative Western immunoblots (upper panel) and quantitative densitometric data (lower panel) show dose-
dependent reversal of VitD3-induced increase in VE-cadherin and CD34 levels in VitD3-treated MSCs with PPP co-
treatment. Data represent mean G standard error of the mean (SEM). One-way analysis of variance (ANOVA) with
Bonferroni post hoc test (VE-cadherin) and Welch’s ANOVA with Dunnett’s T3 post hoc test (CD34), ns = not significant,
*p < 0.05, ****p < 0.0001, n = 3.
(B) The inhibition of VitD3-induced angiogenic phenotype in MSCs by IGF-1R antagonist PPP was further confirmed with
fluorescent detection of VE-cadherin (red) and CD34 (green) in MSCs treated with VitD3 with and without PPP. Scale bar,
20 mm.
(C and D) Representative images (C) and quantitative assessment of branch length (D) show robust augmentation of
capillary-like tube formation by MSCs on Matrigel following VitD3 treatment and inhibition of the same by co-treatment
with IGF-1R antagonist PPP. Scale bar, 100 mm.
Data represent mean G SEM. Welch’s ANOVA with Dunnett’s T3 post hoc test, ns = not significant, *p < 0.05, n = 4.
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MSCs (Figures 1A and 4A). As a secreted protein, IGF-1 has the potential to produce a niche within the sur-
rounding cells by binding to its cognate receptor. To evaluate this niche-forming ability of IGF-1, MSCs
were subjected to either 0.1 nM or 10 nM of VitD3 for 3 days and then cultured in fresh media (without
VitD3) for an additional 5 days. The IGF-1 concentrations in the culture media were quantified by
enzyme-linked immunosorbent assay (ELISA) on days 1, 2, 3, 4, 5, 6, and 8. The IGF-1 concentration in cul-
ture media increased significantly by day 3 with VitD3 stimulation. Compared with the 0.07 ng/mL of IGF-1
in control MSC media, IGF-1 levels in 0.1 nM and 10 nM VitD3-treated MSC groups were 0.44 ng/mL and
0.50 ng/mL, respectively. After switching to VitD3-free culture media, the IGF-1 concentration decreased
slightly on day 4 but then continued to rise subsequently despite the removal of VitD3 stimulation. The
IGF-1 levels in media containing non-treatedMSCs (control) were low (Figure 7A). The IGF-1 levels in media
containing MSCs previously treated with 10 nM of VitD3 were greater compared with levels in 0.1 nM of
VitD3-treated MSCs or control MSCs (Figure 7A).
To examine the paracrine functionality of this niche, MSCs were treated with 10 nM of VitD3 for 3 days and
then changed to fresh medium before co-culture experiments with endothelial cells (Figure 7B). Primary
mouse pulmonary artery endothelial cells (MAECs) were incubated with Cytodex-3 beads, transplanted
into a fibrinogen pad, and maintained in culture. After 3 to 5 days of co-culture in VitD3-free EGM-2MVme-
dium, MAEC beads were co-cultured with MSCs without contact (Figure 7B). Compared with vehicle
control, co-culturing with untreated MSCs (MSC-control) did not enhance branching (Figures 7C and
7D). However, MAECs co-cultured with VitD3-treated MSCs exhibited significantly more branching
compared with MAECs co-cultured with control MSCs. The mean branch length was approximately 2.24-
folds greater and mean protrusions per bead was approximately 4-folds higher in the group co-cultured
with VitD3-treated MSCs compared with respective parameters in the MSC-control group (Figure 7D).
However, the increase in branch length and the number of protrusions from MAEC beads co-cultured
with VitD3-treated MSCs were significantly suppressed by the addition of 1 mMof PPP in the co-culture me-
dium (Figures 7C and 7D). To further substantiate the niche-enhancing attributes of VitD3-treated MSCs,
Figure 6. VitD3/VDR directly binds to the IGF-1 promoter and increases activity
(A and B) The binding of VDR following VitD3 stimulation in MSCs was analyzed by ChIP assay (A) and the relative densities
of DNA bands were quantified (B). Data represent mean G standard error of the mean (SEM). n = 4.
(C) The potential VDR response elements within the promoter region of IGF-1 (top) and the corresponding mutant VDR
response elements (bottom, with mutated nucleotides underlined).
(D) Luciferase reporter constructs containing either wild-type or mutant promoter sequences were transfected into MSCs
for VitD3 stimulation, and the relative levels of luciferase were analyzed following quantification with the internal control.
Data represent meanG SEM. One-way or Welch’s analysis of variance (ANOVA) with Bonferroni or Dunnett’s T3 post hoc
tests, respectively, *p < 0.05, **p < 0.01, ****p < 0.0001, n = 3.
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we also performed similar co-culture assays with murine aortic rings. Pieces of thoracic aorta harvested
from 8-week-old C57BL/6 male mice were cut into 1-mm rings, embedded in Matrigel, and co-cultured
with vehicle, control MSCs, or VitD3-treated MSCs as above. After 5 days, greater micro-vessel outgrowths
surrounding the aortic rings were noted in co-cultures with VitD3-treatedMSCs as compared with theMSC-
control group (Figures 7E and 7F). This enhancement in outgrowths was suppressed by the addition of PPP
to co-culture (Figures 7E and 7F). Together, these results identify IGF-1 as the primary factor secreted by
VitD3-treated MSCs that produces a niche conducive for angiogenesis.
DISCUSSION
The role of VitD3 in angiogenesis remains controversial. Our findings establish a proangiogenic influence
of VitD3 on MSCs, which have been used in clinical trials of cardiac repair with mixed results. The salient
findings include the following: (i) treatment with VitD3 induces proangiogenic genes, increases the expres-
sion of endothelial markers, and promotes MEndoT in MSCs;( ii) VitD3-treated MSCs induce angiogenesis
Figure 7. VitD3-treated MSCs produce an IGF-1 microenvironment for angiogenesis
(A) IGF-1 levels increase in the culture medium in a dose-dependent manner following exposure of MSCs to VitD3. IGF-1
levels continue to increase even after cessation of VitD3 stimulation. Data represent mean G standard error of the mean
(SEM). n = 3.
(B) Cartoon showing the experimental set up with VitD3-treated MSCs in contactless co-culture.
(C and D) Representative images (C) and quantitative data (D) show significant augmentation of bead branching with
VitD3-treated MSCs and reversal of the same with VitD3 and PPP co-stimulated MSCs. Scale bar, 100 mm. Data represent
mean G SEM. One-way analysis of variance (ANOVA) with Bonferroni post hoc test (protrusion length) and Welch’s
ANOVA with Dunnett’s T3 post hoc test (protrusions per bead), ns = not significant, ***p < 0.001, ****p < 0.0001, n = 8-10
per group.
(E and F) Representative images (E) and quantitative assessment of neovascularization surface area (F) from the aortic ring
assay show enhanced sprouting induced by VitD3-treated MSCs. This effect was neutralized when MSCs were treated
with PPP. Scale bar, 100 mm. Data represent mean G SEM. Welch’s ANOVA with Dunnett’s T3 post hoc test, ns = not
significant, **p < 0.01, n = 5 per group.
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both in vitro and in vivo in an IGF-1-dependent manner; (iii) VitD3/VDR complex binds to the IGF-1 pro-
moter to induce IGF-1 expression; and (iv) VitD3 promotes the formation of a proangiogenic niche by
MSCs through enhanced IGF-1 secretion. These results from both in vitro and in vivo studies underscore
a beneficial role of VitD3 in vascular health through angiogenesis. This is particularly appealing because
MSCs have therapeutic potential for diverse diseases, including cardiovascular ischemic diseases (Afzal
et al., 2015; Golpanian et al., 2016). The current data bid well for successful clinical translation of VitD3-
treated MSCs for vasculogenesis in patients with ischemic conditions.
Although sparse evidence suggests that VitD3 can influence cellular fate and inhibit epithelial to mesen-
chymal transition of cancer cells (Upadhyay et al., 2013), its role in endothelial transformation of mesen-
chymal cells remains unknown. The commitment to endothelial cell lineage is important because it in-
creases the capacity for angiogenesis and capillary formation (Ribatti and Crivellato, 2012). The current
results show upregulation of endothelial genes in VitD3-treated MSCs, which is corroborated by increased
expression of both VE-cadherin and CD34, distinctive cell surface markers of endothelial lineage (Breier
et al., 1996; Middleton et al., 2005). Together, these results establish the induction of MEndoT in VitD3-
treated MSCs. The upregulation of other endothelial-related genes including VWF, ICAM-1, and VCAM-
1 further establishes the endothelial nature of MSCs treated with VitD3.
The current results show an increased expression of IGF-1 in MSCs in response to VitD3 treatment. In addi-
tion, the increase in phospho-IGF-1R in VitD3-treated MSCs indicated the activation of IGF-1 signaling in
these cells. In previous studies, IGF-1 has been shown to stimulate migration and tube-forming activities of
endothelial cells, supporting a proangiogenic role (Nakao-Hayashi et al., 1992). The current data also show
that the inhibition of IGF-1 signaling by PPP attenuated the induction of proangiogenic genes and blocked
the acquisition of an endothelial phenotype by VitD3-treated MSCs, indicating a causal role of IGF-1
signaling toward VitD3-induced MEndoT. Concomitant exposure to PPP reduced the ability of VitD3-
treated MSCs to form tubes on Matrigel, consistent with reduced capacity for angiogenesis. The mecha-
nistic basis of IGF-1 induction by VitD3 was further confirmed by the ChIP assay that showed increased
binding of the VitD3 response region on the IGF-1 promoter with increasing doses of VitD3. Collectively,
these findings identify an important role of IGF-1 as the molecular link between VitD3 treatment and induc-
tion of MEndoT in MSCs.
Interestingly, IGF-1 produced in VitD3-treated MSCs exerted additional biological function beyond the in-
duction of MEndoT. Our data show that IGF-1 continued to be secreted by VitD3-treated MSCs, even after
VitD3 was removed from the culture medium. This prolonged secretion of IGF-1 by MSCs enhances an
angiogenic niche conducive to the formation of new vasculature. Indeed, in our contactless co-culture sys-
tem, VitD3-treated MSCs were able to induce angiogenesis in both MAECs and murine aortic rings. These
observations suggest that following in vivo transplantation, VitD3-treated MSCs may induce angiogenesis
through IGF-1-mediated niche formation in recipient tissues.
The precise role of VitD3 in endothelial cell biology and function may vary depending on the context (Ja-
mali et al., 2018). Although an inhibitory influence of VitD3 on angiogenesis has been reported in the
setting of malignancy (Mantell et al., 2000), epidemiological studies have identified an adverse association
between VitD3 deficiency and incident cardiovascular events (Wang et al., 2008). In this context, the current
findings identify two important mechanisms (Figure 8) through which VitD3 may augment vascularization.
First, the generation of angiogenic cells from transplantedMSCs through VitD3-inducedMEndoTmay play
a direct role toward increasing vascularity. Our data show an important role of VitD3-induced IGF-1 in this
conversion of MSCs into cells that may directly effect angiogenesis. Second, the protracted secretion of
IGF-1 by VitD3-treated MSCs may amplify the vasculogenic effects of donor MSCs by enabling the forma-
tion of proangiogenic niches at sites of MSC transplantation, with potential recruitment of host cells and
additional vascularization. Collectively, these observations support an important role of VitD3 toward
the promotion of angiogenesis, and may explain the increased cardiovascular events in patients with
VitD3 deficiency. These findings also support the potential efficacy of VitD3-treated MSCs for therapeutic
angiogenesis in ischemic tissues.
Limitations of the study
Although epidemiological evidence has identified an association between VitD3 deficiency and adverse
cardiovascular events, it is difficult to reproduce the vascular effects of human VitD3 deficiency in isolation
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in a mouse model. Therefore, we focused on the elucidation of potential mechanisms through which VitD3
may exert vascular benefits. Although our current results identify how VitD3 signaling may influence angio-
genesis, additional studies in a model of ischemia and VitD3-treated MSC transplantation in vivo will be
necessary in the future.
Resource availability
Lead contact
Further information and request for resources and reagents should be directed to Prof. Buddhadeb Dawn
(buddha.dawn@unlv.edu).
Materials availability
Any unique reagent or material will be available from the lead contact upon request.
Data and code availability
The published article includes all data generated or analyzed during this study. This study did not generate
any unique code.
METHODS
All methods can be found in the accompanying transparent methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.102272.
ACKNOWLEDGMENTS
This study was supported in part by NIH grant R01 HL-117730.
Figure 8. Schematic representation of dual mechanisms underlying VitD3-induced angiogenesis
VitD3 induces IGF-1 in MSCs, which promotes angiogenesis through MEndoT. In addition, VitD3-treated MSCs continue
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Animal Care and Use  
The current study was approved by the Animal Care and Use Committee of the University of 
Kansas Medical Center, and performed in accordance with the Guide for the Care and Use of 
laboratory Animals (Department of Health and Human Service, Publication No. [NIH] 86-23). 
 
Mesenchymal Stem Cell Isolation and Culture  
Mesenchymal stem cells (MSCs) were collected from bone marrow as described previously with 
modifications (Labedz-Maslowska et al., 2015). In brief, the cavities of tibia and femur bones were 
collected from 8-week old male C57BL/6 mice by flushing with DMEM/F-12 media. The flushed 
cells were then purified with Ficoll balanced liquid (GE healthcare, 17-1440-02) and plated for 72 
h, following which nonadherent cells were discarded, and adherent MSCs expanded in complete 
medium (DMEM/F-12 with 10% FBS).  
 
Antibodies and Reagents  
Antibodies against the following protein/epitopes were used in this study: CD34 (NOVUS; NB600-
1071), VE-cadherin (NOVUS; AF1002), VEGF (Santa Cruz; sc-152), FLK1 (Santa Cruz; sc-
57135), VDR (Cell Signaling; 12550), IGF-1 (Santa Cruz; sc-1422), IGF-1R (Cell Signaling; 
#9750), phospho-IGF-1R (Cell Signaling; #3021), phospho-ERK1/2 (Cell Signaling; #4370), ß-
Actin (Santa Cruz; sc-1616) and PE-labeled CD34 (BD Biosciences, 551387), FITC-labeled CD31 
(eBioscience, E00252-1631).   
 
Reagents were obtained from the following sources: DMEM with high glucose were from Gibco 
(11330-032); EGM-2MV endothelial cell culture buckets were from Lonza (cc-3162); FITC-labeled 
Isolectin B4 were from Vector Laboratories Ltd; Fetal Bovine Serum (FBS) was from Gibco; qPCR 
amplification kits were purchased from Midsci; Matrigel matrix was from BD Biosciences. The 
luciferase reporter assay kit was from Promega. The IGF-1R specific inhibitor PPP, VitD3, 
Fibrinogen and the Cytobeads-3 were all from Sigma. The CellTrace™ Calcein Green, AM was 
from ThermoFisher Scientific (C34852). The IGF-1 mouse ELISA Kit was from Invitrogen 
(EMIGF1). 
 
Capillary-like Tube Formation Assay   
The capillary-like tube formation assay was performed as previously described (Khoo et al., 2011). 
Briefly, twenty-four well plates were coated with 100 µL/well of Matrigel matrix (BD Biosciences, 
354267) and incubated at 37°C for 30 min. VitD3-treated MSCs and control MSCs were seeded 
at a density of 1x105 cells/well in the EGM-2MV media. Cells were incubated for 6 h at 37°C and 
stained with CellTrace™ Calcein Green, AM. Tube formation was examined every 2 h and phase-
contrast images of MSC-derived cells on Matrigel were acquired with an Olympus IX71 inverted 
microscope. Tube length on four digital images from each group was measured using ImagePro 
Plus software, and the total length of branches on each image was calculated. These data were 
expressed as ratios relative to the control MSC group. 
 
Xenograft in vivo Angiogenesis Assay 
For the in vivo angiogenesis study, MSCs mixed with Matrigel were used (Melero-Martin and 
Bischoff, 2008). Briefly, MSCs were cultured in T175 flasks with DMEM/F-12 supplemented with 
10% FBS. After 3 days of VitD3 treatment, 1x107 cells in each group were mixed with ice-cold 
Matrigel and subcutaneously injected into both flanks (two injections per mouse) of 8-week old 
C57BL/6 male mice. Three mice in each group received a total of six injections. Three weeks later, 
mice were euthanized and explanted Matrigel plugs were evaluated for color change due to 
perfusion with blood. Matrigel plugs were sectioned and stained with fluorescein-conjugated 
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isolectin B4 followed by image acquisition using a Leica laser scanning confocal microscope 
(Leica TCS SPE) (Chen et al., 2017). Capillaries were counted on images from 4 plugs in each 
group and expressed per mm2.  
 
Gene Expression Analysis by Quantitative Real-time PCR  
Total RNA was isolated from MSCs with TRIzol reagent (Invitrogen, 15596018) and 1 µg of RNA 
from each sample was reverse transcribed into cDNA by the First-strand cDNA synthesis system 
(Bio-Rad, 170-8841). The expression of genes related to angiogenesis and neovascularization 
was examined by qRT-PCR using Bullseye EvaGreen qPCR Master Mix (Midsci, BEQPCR-LR), 
cDNA template, and forward and reverse primers (Table S1) using ViiA™ 7 Real-Time PCR 
System (Applied Biosystems). GAPDH was used as endogenous control and 2-ΔΔCT method was 
used for data analysis (Zhao et al., 2019).  
 
Western Immunoblotting  
Cell extracts were lysed in radio-immunoprecipitation assay buffer (RIPA) supplemented with 
protease inhibitors (Roche Diagnostics, 04693124001). Protein concentration was determined by 
Pierce BCA Protein Assay kit (Fisher, 23224). SDS-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) was performed following standard methods (Zhao et al., 2019). Following transfer, the 
membrane was probed with primary antibodies and labelled using fluorescently conjugated 
secondary antibodies (LI-COR Biosciences, 925-68072 and 925-32213) visualized using an 
Odyssey scanner (LI-COR Biosciences). Densitometry analysis was performed using the Image 
Studio software supplied by LI-COR Bioscience. The densitometric values of all bands of interest 
were normalized to β-actin (loading control).   
 
Immunofluorescence Assay  
MSCs were plated on glass bottom plates. Following VitD3 treatment, MSCs were rinsed with 
PBS, fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100 (BD 
Cytofix/Cytoperm fixation/permeabilization kit; BD biosciences, 554714), blocked with 10% 
donkey serum for 1 h, and incubated with primary antibodies overnight at 4°C followed by 
secondary antibodies (Invitrogen, A16004 and A18740). Image acquisition was performed using 
an Olympus IX71 fluorescent microscope. 
 
Flow Cytometry  
VitD3-treated MSCs were immunostained in FACS buffer (0.1% BSA in PBS) with PE-conjugated 
anti-CD34 and FITC-conjugated anti-CD31 antibodies. Flow cytometric analysis of endothelial 
cell surface markers was performed using a BDTM LSR II and FlowJo software following 
established methods (Adamiak et al., 2018).  
 
Chromatin Immunoprecipitation  
To identify potential VDR protein response elements, we searched the IGF-1 promoter region for 
the VDR binding motif (Ramagopalan et al., 2010). For the chromatin immunoprecipitation assay, 
MSCs were subjected to VitD3 treatment, and then cross-linked with 1% formaldehyde for 15 
mins at room temperature. The crosslinking was stopped by the addition of 125 nM glycine (final 
concentration). Cell lysates were sonicated to generate DNA fragments with an average size of 
less than 1,000 bp and immunoprecipitated with VDR-specific antibody. Bound DNA fragments 
were eluted and amplified by PCR with specific primers (Table S1).  
 
Plasmid Construction and Luciferase Reporter Assay  
For the reporter assay, the IGF-1 genomic fragments (-2111 to +11) containing either wild-type 
or mutant VDR binding regions (Figure 6A) were amplified from murine genomic DNA using 
Phusion High-Fidelity DNA Polymerase (NEB, M0530) and subcloned into pGL3-basic vector 
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(Promega, catalog # E1751). The site-directed mutagenesis of the VDR binding region was 
performed following the In-Fusion® HD Cloning Plus Kit (Takara, Japan) with IGF-1 mutation 
primers (Table S1). The DNA fragment of the IGF-1 promoter was subcloned into the firefly-
luciferase reporter vector, pGL3-Basic (renamed pGL3-IGF-1-wt). The VDR binding elements 
within the IGF-1 promoter region were mutated and subcloned into the pGL3-Basic vector and 
renamed pGL3-IGF-1-mut1 and pGL3-IGF-1-mut2 (Figure 6A). 
 
The luciferase reporter assay was performed following the manufacturer’s protocol. Briefly, MSCs 
were transfected with reporter vectors (pGL3-IGF-1-wt, pGL3-IGF-1-mut1 and pGL3-IGF-1-mut2) 
by LipofectamineTM 3000 (Invitrogen, L3000001). After 48 h of VitD3 treatment, luciferase activity 
was determined using a Dual Luciferase Assay System (Promega, E2920). Transfection 
efficiency was normalized on the basis of Renilla luciferase activity co-transfected with pRL-TK 
vector (Promega, E2241).  
 
IGF-1 ELISA assay 
IGF-1 concentration in culture media was quantified using Invitrogen Mouse IGF-1 ELISA Kit 
(EMIGF1) following the manufacturer’s instructions. 
 
Cytodex Beads Branching Assay  
The C57BL/6 Mouse Pulmonary Artery Endothelial Cells (MAECs) from Creative Bioarray (CSC-
C4244X) are isolated from pulmonary artery of pathogen-free mice and maintained using EBM-
2MV complete media. The Cytodex bead branching assay was performed as previously described 
(Nakatsu et al., 2003). Briefly, MAECs were incubated in suspension with Cytodex beads at a 
ratio of 1x106 cells per 1,200 beads for 4 h at 37°C with occasional agitation. After dilution in the 
pre-gel solution at a concentration of 500 beads per mL, MAEC beads were maintained on 
Fibrinogen (Type I) pre-coated 12-well plates and co-cultured with VitD3-treated MSCs in EGM-
2MV media. To block IGF-1 activity, 1 µM of PPP was added to the VitD3-MSCs and MAEC beads 
co-culture system. Medium was changed every other day. Phase contrast images of branching 
tubes were acquired. The length of 8 randomly selected protrusions from each of 10 independent 
beads in each group was measured using the ImagePro Plus software and the average lengths 
calculated. The number of protrusions on each of these independent beads were also counted on 
digital images.  
 
Aortic Ring Assay for Ex Vivo Angiogenesis  
Aortic ring assay was performed according to published methods (Bellacen and Lewis, 2009). 
Thoracic aortic segments were harvested from 8-week-old male C57BL/6 mice under a dissecting 
microscope, cut into 1 mm sections, and embedded in Matrigel-coated plates. Aortic sections 
were then co-cultured with VitD3-treated MSCs and maintained in EBM-2MV endothelial culture 
medium. To examine the role of IGF-1, PPP was added to block IGF-1 activity in the co-culture 
system. Five microscopic images were acquired from each group. Using ImagePro Plus software, 
the areas were drawn manually. The total aortic spouting area (surface area of the aortic ring plus 
the sprouting area) as well as the area of the aortic ring alone were measured in each digital 
image. Data were expressed as the ratio of the total aortic sprouting area and the aortic ring 
surface area alone.   
 
Statistical Analysis  
Data are expressed as means ± SEM. Statistical comparisons were performed using the SPSS 
software version 26.0 (IBM, Armonk, NY). One-way or Welch’s ANOVA with Bonferroni or 
Dunnett’s T3 post hoc tests, respectively, were performed to assess significance. Significance 
for all statistical tests was shown in figures for not significant (NS), p < 0.05 (*), p < 0.01 (**), p < 
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Key Resources  
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
    
anti-CD34 Novus Biologicals NB600-1071 
anti-VE-cadherin  Novus Biologicals AF1002 
anti-VEGF Santa Cruz Biotechnology sc-152 
anti-FLK1  Santa Cruz Biotechnology sc-57135 
anti-VDR  Cell Signaling Technology #12550 
anti-IGF-1  Santa Cruz Biotechnology sc-1422 
anti-IGF-1R Cell Signaling Technology #9750 
anti-pIGF-1R  Cell Signaling Technology #3021 
anti-pERK1/2  Cell Signaling Technology #4370 
anti-β-Actin  Santa Cruz Biotechnology sc-1616 
PE-labeled anti-CD34    BD Biosciences #551387 
FITC-labeled anti-CD31 eBioscience E00252-1631 
Donkey anti-Goat IgG (H+L), TRITC Invitrogen A16004 
Donkey anti-Rat IgG (H+L), FITC Invitrogen A18740 
IRDye® 800CW Donkey anti-Rabbit IgG LI-COR Biosciences 925-32213 
IRDye® 680RD Donkey anti-Mouse IgG LI-COR Biosciences 925-68072 
GSL I - Isolectin B4 Vector Laboratories Ltd FL1201 
Chemicals, Peptides, and Recombinant Proteins 
  
DMEM/F-12 Corning 10-090-CV 
FBS Gibco 26140-079 
Ficoll GE healthcare 17-1440-02 
DMEM  Gibco 11330-032 
1α,25-Dihydroxyvitamin D3 Sigma-Aldrich D1530-10UG 
Cytodex 3 microcarrier beads Sigma-Aldrich C3275-10G 
Fibrinogen Sigma-Aldrich F6755 
Picropodophyllin Sigma-Aldrich 407247 
Phusion High-Fidelity DNA Polymerase NEB M0530 
Matrigel matrix BD Biosciences 354267 
ImagePro Plus software Media Cybernetics http://www.mediacy.com/imagepro 
TRIzol reagent Invitrogen 15596018 
EverGreen qPCR master mix (2x) MIDSCI BEQPCR-LR 
BSA Fisher Scientific BP9706100 
Donkey serum Fisher Scientific 56-646-05ML 
RIPA buffer Fisher Scientific AAJ63306AK 
Protease inhibitors Roche Diagnostics 04693124001 
Triton X-100 Fisher Scientific BP151-100 




LipofectamineTM 3000 Invitrogen L3000001 
Critical Commercial Assays 
    
Cytofix/Cytoperm fixation/permeabilization kit  BD Bisosciences 554714 
In-Fusion® HD Cloning Plus Kit Takara 638909 
BCA protein assay kit Fisher Scientific 23224 
Lonza Walkersville EGM 2 BULLET KIT  Lonza cc-3162 
Fist strand cDNA synthesis system Bio-Rad 170-8841 
Dual-Glo™ Luciferase Assay System Promega PR-E2920 
IGF-1 Mouse ELISA Kit Invitrogen EMIGF1 
Recombinant DNA 
    
pGL3-basic vctor Promega E1751 
pRL-TK vector Promega E2241 
Experimental Models: Organisms/Cell 
    
C57BL/6 mouse The Jackson Laboratory  







Table S1. Primers used in the study, related to Figures 1, 4, 6. 
 
PRIMERS FOR QPCR 
NAME SEQUENCE 5’-3’ GENE ID 
GAPDH-F AGGTCGGTGTGAACGGATTTG NM_008084 
GAPDH-R TGTAGACCATGTAGTTGAGGTCA  
c-Myc-F GCCCCTAGTGCTGCATGAG NM_010849.4 
c-Myc-R CCACAGACACCACATCAATTTCTT  
Oct4-F GGAGTCTGGAGACCATGTTTCTG NM_013633.2 
Oct4-R GAACCATACTCGAACCACATCCTT  
SSEA1-F ACGGATAAGGCGCTGGTACTA NM_010242 
SSEA1-R GGAAGCCATAGGGCACGAA  
VEGF-F CTGCCGTCCGATTGAGACC MMU50279 
VEGF-R CCCCTCCTTGTACCACTGTC  
Endothelin-1-F GCACCGGAGCTGAGAATGG NM_010104 
Endothelin-1-R GTGGCAGAAGTAGACACACTC  
VCAM-1-F AGTTGGGGATTCGGTTGTTCT NM_011693 
VCAM-1-R CCCCTCATTCCTTACCACCC  
ICAM-1-F GTGATGCTCAGGTATCCATCCA NM_010494 
ICAM-1-R CACAGTTCTCAAAGCACAGCG  
VWF-F CTTCTGTACGCCTCAGCTATG NM_011708 
VWF-R GCCGTTGTAATTCCCACACAAG  
FLK1-F TTTGGCAAATACAACCCTTCAGA NM_010612 
FLK1-R GCAGAAGATACTGTCACCACC  
PDGFrb-F TTCCAGGAGTGATACCAGCTT NM_001146268 
PDGFrb-R AGGGGGCGTGATGACTAGG  
αSMA-F GTCCCAGACATCAGGGAGTAA NM_007392 
αSMA-R TCGGATACTTCAGCGTCAGGA  
IGF1-F CTGGACCAGAGACCCTTTGC NM_001111274 
IGF1-R GGACGGGGACTTCTGAGTCTT  
CD34-F AAGGCTGGGTGAAGACCCTTA NM_001111059 
CD34-R TGAATGGCCGTTTCTGGAAGT  
VE-cadherin-F CACTGCTTTGGGAGCCTTC NM_009868 
VE-cadherin-R GGGGCAGCGATTCATTTTTCT  
PRIMERS FOR RECONSTRUCTION 
IGF1-F-XhoI GCACTCGAGTCTCACACCAGGTTTCTAA NM_010512 
IGF1-R-HindIII CGGTACCAAGCTTACAGGAAACAGCT  
Mut-F1 TCCTTCGCCAGTAGGTAGTGACAGGCATC  
Mut-R1 GATGCCTGTCACTACCTACTGGCGAAGGA  
Mut-F2 TACCCTCACTATGTCACAATTAACAGCATTG   
Mut-R2 CAATGCTGTTAATTGTGACATAGTGAGGGTA   
PRIMERS FOR ChIP ASSAY 
ChIP-IGF1-F1 CATCATAACCCTGGAGAGAGTATTG NM_010512 
ChIP-IGF1-R1 GCTGAGATCTGGGATGGATTG   
